Why is "Raloxifene" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-04-08 23:09:51
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
Raloxifene entered the ranking for the first time today at position #. This is its highest position ever recorded.
Trend History
This topic has appeared in the English Wikipedia rankings 1 time. It first appeared on 2026-04-08 and was most recently seen on 2026-04-08.
Wikipedia Overview
Raloxifene, sold under the brand name Evista among others, is a medication used to prevent and treat osteoporosis in postmenopausal women and those on glucocorticoids. For osteoporosis it is less preferred than bisphosphonates. It is also used to reduce the risk of breast cancer in those at high risk. It is taken by mouth.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
Raloxifene relaxes the rat aorta via a mitochondria-dependent mechanism - Nature
-
Raloxifene: An Alternative for Non-Binary and Gender-Affirming Care - GenderGP
-
Researchers Identify Ocular AEs of Two Breast Cancer Treatments - Review of Optometry
-
Preventing Breast Cancer with Tamoxifen - McLeod Health
-
Effects of Raloxifene on Cardiovascular Events and Breast Cancer in Postmenopausal Women - NEJM
-
Intelligence modeling of solubility of raloxifene and density of solvent for green supercritical processing of medicines for enhanced solubility - Nature
-
Raloxifene: A star above par with tamoxifen - Fred Hutchinson Cancer Center
-
Side Effects of Evista (Raloxifene) You Should Know About - GoodRx
-
Raloxifene May Improve Symptoms in Older Women With Refractory Schizophrenia - Psychiatry Online
-
Effect of Raloxifene on Stroke and Venous Thromboembolism According to Subgroups in Postmenopausal Women at Increased Risk of Coronary Heart Disease - American Heart Association Journals
-
Raloxifene as an Adjuvant Therapy for Patients With Schizophrenia: An Up-To-Date Systematic Review and Meta-Analysis - Wiley Online Library
-
Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal Women - NEJM
-
and correlation of drug solubility via hybrid machine learning and gradient based optimization - Nature
-
Repurposing the estrogen receptor modulator raloxifene to treat SARS-CoV-2 infection - Nature
-
Risk-benefits assessment of tamoxifen or raloxifene as chemoprevention for risk reduction of breast cancer among BRCA1 and BRCA2 carriers: a meta-analysis - Nature
-
Quality of life and patient satisfaction with raloxifene/cholecalciferol combination therapy in postmenopausal women - Nature
-
Characterization of raloxifene as a potential pharmacological agent against SARS-CoV-2 and its variants - Nature
-
Comparative safety and effectiveness of alendronate versus raloxifene in women with osteoporosis - Nature
-
Raloxifene prevents stress granule dissolution, impairs translational control and promotes cell death during hypoxia in glioblastoma cells | Cell Death & Disease - Nature
-
Lilly Announces Review of Data on Long-Term Raloxifene Treatment for Postmenopausal Osteoporosis Published in Current Medical Research & Opinion - Eli Lilly
-
Raloxifene Stimulates Estrogen Signaling to Protect Against Age- and Sex-Related Intervertebral Disc Degeneration in Mice - frontiersin.org
-
Both Raloxifene and Estrogen Reduce Major Cardiovascular Risk Factors in Healthy Postmenopausal Women : - American Heart Association Journals
-
Adjunctive raloxifene treatment improves attention and memory in men and women with schizophrenia - Nature
-
Long-Term Raloxifene in a Woman at High Risk for Breast Cancer - NEJM
-
Cerebral Venous Sinus Thrombosis During Raloxifene Therapy: A Case Report - cureus.com
-
FDA Approves Lilly's Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women - Eli Lilly
-
Effects of Raloxifene Combined with Low-dose Conjugated Estrogen on the Endometrium in Menopausal Women at High Risk for Breast Cancer - www.elsevier.com
-
Effect of Raloxifene on Prevention of Dementia and Cognitive Impairment in Older Women: The Multiple Outcomes of Raloxifene Evaluation (MORE) Randomized Trial - Psychiatry Online
-
Evista® Approved for Prevention of Breast Cancer - news.cancerconnect.com
-
Medication Use to Reduce Risk of Breast Cancer: Recommendation Statement - aafp.org
-
Results of Nationwide Breast Cancer Prevention Trial Show Osteoporosis Drug Raloxifene is as Effective as Tamoxifen in Preventing Invasive Breast Cancer; Vanderbilt-Ingram Cancer Center is Only Regional Participant - Vanderbilt Health News
-
Adjunctive Raloxifene for Women With Schizophrenia - Psychiatric Times
-
Raloxifene increases the risk of gastroesophageal reflux disease, Barrett's esophagus, and esophageal stricture in postmenopausal women with osteoporosis - Wiley Online Library
-
Effects of the Selective Estrogen Receptor Modulator Raloxifene on Coronary Outcomes in The Raloxifene Use for the Heart Trial: - American Heart Association Journals
-
Estrogen-like Activity of Tamoxifen and Raloxifene on NMDA Receptor Binding and Expression of its Subunits in Rat Brain - Nature
-
Discussing medication therapies that can help prevent breast cancer in high risk patients - Mayo Clinic News Network
-
Evaluating the Effects of Follow-Up Therapy After Denosumab Discontinuation in Postmenopausal Osteoporosis - Rheumatology Advisor
-
Testing osteoporosis drug for COVID-19 treatment - CORDIS | European Commission
-
Combination Teriparatide and Raloxifene Therapy for Postmenopausal Osteoporosis: Results From a 6-Month Double-Blind Placebo-Controlled Trial - Wiley Online Library
-
Effects of Ovarian Steroids and Raloxifene on Proteins that Synthesize, Transport, and Degrade Serotonin in the Raphe Region of Macaques - Nature
-
Administration of omega-3 fatty acids and Raloxifene to women at high risk of breast cancer: interim feasibility and biomarkers analysis from a clinical trial - Nature
-
Differential Effects of Teriparatide on BMD After Treatment With Raloxifene or Alendronate - Wiley Online Library
-
Tamoxifen and raloxifene slow down the progression of muscular dystrophy - EurekAlert!
-
Raloxifene Treatment Enhances Brain Activation during Recognition of Familiar Items: a Pharmacological fMRI Study in Healthy Elderly Males - Nature
-
Bone Turnover Matters: The Raloxifene Treatment Paradox of Dramatic Decreases in Vertebral Fractures Without Commensurate Increases in Bone Density - Wiley Online Library
-
OSU study: Osteoporosis drug may treat breast and liver cancers - Oregon State University
-
MD Progression Delayed with Use of Tamoxifen and Evista in Mouse Study - Muscular Dystrophy News
-
Exemestane for Breast-Cancer Prevention in Postmenopausal Women - NEJM
-
Chronic Kidney Disease Should Not Prevent Women from Taking the Osteoporosis Drug Raloxifene | Newswise - Newswise
-
Hanmi’s RaboneD dominates osteoporosis therapy market - Korea Biomedical Review
-
Lasofoxifene in Postmenopausal Women with Osteoporosis - NEJM
-
Extracorporeal shock waves alone or combined with raloxifene promote bone formation and suppress resorption in ovariectomized rats - journals.plos.org
-
Medicines to prevent breast cancer - Harvard Health
-
Eli Lilly and Company Submits New Drug Application for EVISTA for Reduction of Invasive Breast Cancer Risk in Postmenopausal Women - Eli Lilly
-
Cancer prevention drugs won’t reach potential until we fix licensing - The Conversation
-
Medications for Risk Reduction of Primary Breast Cancer in Women: U.S. Preventive Services Task Force Recommendation Statement - ACP Journals
-
High risk for breast cancer? You might benefit from preventive medication - Harvard Health
-
Standardized Bending and Breaking Test for the Normal and Osteoporotic Metaphyseal Tibias of the Rat: Effect of Estradiol, Testosterone, and Raloxifene - Wiley Online Library
-
Osteoporosis – pharmacological prevention and management in older people - Royal Australian College of General Practitioners (RACGP)
-
Modulation by Estrogen-Receptor Directed Drugs of 5-Hydroxytryptamine-2A Receptors in Rat Brain - Nature
-
New Breast Cancer Drug Has Fewer Side Effects - WUNC News
-
Tratamiento secuencial en osteoporosis. Nuevas tendencias - SciELO España
-
Increasing co-promotion deals among drugmakers herald new industrial trend - Korea Biomedical Review
-
New FORTEO® and EVISTA® Data to be Presented at Premiere Scientific Meeting for Bone and Mineral Research - PR Newswire
-
New Breast Cancer Drug Has Fewer Side Effects - KPBS
-
Baystate oncologist Grace Makari-Judson supports use of drugs for women at high risk for breast cancer - MassLive
-
Reducing the odds - Ocala StarBanner
-
Endocrine Therapy in Breast Cancer: Making Sense of the ‘Word Salad’ - American Association for Cancer Research (AACR)
-
Gynecomastia: A systematic review of pharmacological treatments - frontiersin.org
-
Mayo Clinic Q and A: Finding the right osteoporosis medication - Mayo Clinic News Network
-
Eli Lilly's Evista shows efficacy in osteoporosis treatment - The Pharma Letter
-
Tamoxifen-class drugs cut breast cancer risk by more than third - Nursing Times
-
Third-generation SERMs for osteoporosis - Irish Medical Times
-
Dr Reddy's launches osteoporosis drug in US market - Business Standard
-
Zydus Alidac Launches Osteoporosis Drug - Business Standard
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.